iBio, Inc. (IBIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 600 MADISON AVENUE, SUITE 1601
NEW YORK, NY 10022-1737
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
6/30/2023
12/31/2022
MRQ
6/30/2022
6/30/2021
6/30/2020
6/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:7,5793,94928,67296,97455,1124,421
Cash and cash equivalents4,3013,69622,67677,40455,1124,421
Short-term investments    19,570  
Other undisclosed cash, cash equivalents, and short-term investments3,2782535,996   
Restricted cash and investments3,025     
Receivables  2,6391,0004267597
Inventory, net of allowances, customer advances and progress billings   3,900   
Inventory   3,900   
Asset, held-for-sale, not part of disposal group18,06520,457    
Other undisclosed current assets(2,410)11,19011,4987,1976,561290
Total current assets:26,25938,23545,070104,59761,7484,808
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization6107467426,11127,616
Operating lease, right-of-use asset2,7222,8735,020  
Property, plant and equipment4,2194,24536,6618,6283,65724,380
Intangible assets, net (including goodwill)5,3885,3984,8519521,1441,374
Intangible assets, net (excluding goodwill)5,3885,3984,8519521,1441,374
Prepaid expense   74   
Restricted cash and investments2532535,996   
Other undisclosed noncurrent assets1,756501,6606,6802424
Total noncurrent assets:14,94813,56554,33642,37132,44125,778
TOTAL ASSETS:41,20751,80099,406146,96894,18930,586
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,8839,00311,0945,2552,8641,966
Employee-related liabilities3,066   
Accounts payable1,8494,0024,2642,2541,7591,001
Accrued liabilities4,0345,0013,7643,0011,105965
Deferred revenue  881004231,810
Debt13,20916,27022,207967562213
Disposal group, including discontinued operation1,9411,947    
Contract with customer, liability1,279
Other undisclosed current liabilities549467(2,965)   
Total current liabilities:21,58227,77530,4366,6455,2363,458
Noncurrent Liabilities
Long-term debt and lease obligation3514905,48531,75532,34624,671
Long-term debt, excluding current maturities     339 
Capital lease obligations24,671
Finance lease, liability3514903031,75532,007
Liabilities, other than long-term debt3,1253,324    
Operating lease, liability3,1253,3245,455  
Other undisclosed noncurrent liabilities7681,388(5,455)   
Total noncurrent liabilities:4,2445,2025,48531,75532,34624,671
Total liabilities:25,82632,97735,92138,40037,58228,129
Equity
Equity, attributable to parent15,38118,82363,485108,58556,6182,463
Common stock2012921714020
Additional paid in capital304,301294,591287,619282,058206,931108,295
Accumulated other comprehensive loss  (167)(213)(63)(33)(31)
Accumulated deficit(288,940)(275,613)(223,930)(173,627)(150,420)(105,821)
Equity, attributable to noncontrolling interest    (17)(11)(6)
Total equity:15,38118,82363,485108,56856,6072,457
TOTAL LIABILITIES AND EQUITY:41,20751,80099,406146,96894,18930,586

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Revenues 2,0042,3832,3711,6382,018
Cost of revenue
(Cost of Goods and Services Sold)
  (63)(216)(1,462)  
Gross profit: 1,9412,1679091,6382,018
Operating expenses(29,343)(49,228)(51,857)(32,020)(15,641)(17,806)
Operating loss:(29,343)(47,287)(49,690)(31,111)(14,003)(15,788)
Nonoperating income (expense)32(257)(614)7,898(2,441)(1,809)
Investment income, nonoperating2132491851522591
Interest and debt expense(83)(507)(1,412)(2,454)(2,466)(1,900)
Loss from continuing operations before income taxes:(29,394)(48,051)(51,716)(25,667)(18,910)(19,497)
Income tax benefit    55  
Other undisclosed income from continuing operations8332    
Loss from continuing operations:(29,311)(48,019)(51,716)(25,612)(18,910)(19,497)
Loss before gain (loss) on sale of properties:(48,049)(51,716)(25,612)(18,910)(19,497)
Loss from discontinued operations(35,699)(33,583)    
Other undisclosed net income 4751,4122,3992,4661,900
Net loss:(65,010)(81,127)(50,304)(23,213)(16,444)(17,597)
Net income attributable to noncontrolling interest   1654
Net loss attributable to parent:(65,010)(81,127)(50,303)(23,207)(16,439)(17,593)
Other undisclosed net income (loss) available to common stockholders, basic35,69933,583(88)(260)(21,821)(260)
Net loss available to common stockholders, diluted:(29,311)(47,544)(50,391)(23,467)(38,260)(17,853)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Net loss:(65,010)(81,127)(50,304)(23,213)(16,444)(17,597)
Other undisclosed comprehensive income (loss)213(76)(150)(30)(2)(1)
Comprehensive loss:(64,797)(81,203)(50,454)(23,243)(16,446)(17,598)
Comprehensive income, net of tax, attributable to noncontrolling interest   1654
Comprehensive loss, net of tax, attributable to parent:(64,797)(81,203)(50,453)(23,237)(16,441)(17,594)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: